Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer.
Nucl Med Biol
; 50: 47-49, 2017 Jul.
Article
en En
| MEDLINE
| ID: mdl-28438468
In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oligopéptidos
/
Neoplasias de la Próstata
/
Radioisótopos de Flúor
/
Colina
/
Ácido Edético
/
Tomografía Computarizada por Tomografía de Emisión de Positrones
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
/
Male
Idioma:
En
Revista:
Nucl Med Biol
Asunto de la revista:
BIOLOGIA
/
MEDICINA NUCLEAR
Año:
2017
Tipo del documento:
Article
Pais de publicación:
Estados Unidos